healthcare-investing
(7)
B Capital Built a $12 Billion Bridge Between Founders and the Corporate World
Most venture firms promise a network. B Capital wired one into its operating model - then stretched it from Silicon Valley to Singapore and from seed rounds to late-stage growth.
The Quiet Compounders of Park Avenue
For 40-plus years, Harvest Partners has bought unglamorous middle-market companies and held them long enough to matter. Here is how a relationship-first shop on Park Avenue turned patience into a $20-billion franchise.
Inspired Capital Wants the Napkin, Not the Hype Cycle
The New York firm has nearly $900 million, fewer than 10 new bets a year and a taste for founders still sketching the future. Its wager is that operating experience and patient conviction can beat venture capital by trend cycle.
The Private Equity Firm Betting That Public Problems Can Produce Private Returns
The Vistria Group has built a $17 billion investment platform around a provocative premise: the hardest systems to navigate may also hold the most durable opportunities to create value.
Lightspeed Built a $9 Billion Bet on the Long Game
Lightspeed has grown from an enterprise-focused Silicon Valley partnership into a global, multi-stage investor. Its newest funds reveal the real strategy: specialist judgment, patient capital and enough range to keep backing a company as the stakes rise.
Kevin Xu
Kevin Xu is the Chairman and CEO of ClinChoice, a global full-service contract research organization (CRO) with more than 30 years of history, roughly 4,000 staff, and operations across 15+ countries. He arrived in the corner office from the investor's side of the table: for over 15 years he was a Managing Director at Goldman Sachs, where he built and ran the firm's Asia-Pacific Healthcare and Life Sciences investing practice, leading deals across biotech, pharma, medtech, CROs/CDMOs and digital health. Trained in neuroscience and clinical psychology before finance, he is an outspoken advocate for destigmatizing mental illness and an unlikely wake-surfer.
Giovanni Ahern
Giovanni Ahern is an Investing Partner at Andreessen Horowitz (a16z), one of Silicon Valley's most influential venture capital firms, where he focuses on growth-stage investments. A dual-degree MIT graduate in Mathematics and Computer Science with Economics, Ahern built his investment acumen through roles at Blackstone, Houlihan Lokey, and three years as a Private Equity Associate at Bain Capital specializing in healthcare and technology. Joining a16z in September 2025, he brings a quantitative rigor and cross-sector perspective to backing the next generation of market-defining technology companies.